Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings
ALNY SEC filings moved a median of -0.21% by the close. ALNY SEC filings — 10-K, 10-Q, 8-K and the rest — each read against the price at its own news timestamp. Back to the ALNY overview →
54 measured ALNY SEC filing events.
Where these ALNY SEC filings landedvs 54 measured ALNY SEC filing reactions
| Middle 50% of ALNY SEC filing reactions | -1.46% to +2.26% |
|---|---|
| Median reaction (to close) | -0.21% |
| Measured reactions | 54 |
Point-in-time · zero look-ahead
Half of the 54 ALNY SEC filing events with a measured close landed between -1.46% and +2.26%; 46% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -1.62% | -8.27% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 30 | SEC filing · Form 8-K | -1.62% | -8.27% | |
| Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics | Press release | -0.36% | +2.16% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: May 20 | SEC filing · Form 8-K | +1.04% | +4.12% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -3.62% | +0.65% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Apr 30 | SEC filing · Form 8-K | -3.62% | +0.65% | |
| Form ARS ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | -1.42% | +0.01% | |
| Form DEF 14A ALNYLAM PHARMACEUTICALS, For: May 20 | SEC filing · Form DEF | -1.42% | +0.01% | |
| Form DEFA14A ALNYLAM PHARMACEUTICALS, | SEC filing · Form DEFA14A | -1.42% | +0.01% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Mar 02 | SEC filing · Form 8-K | +0.01% | -0.98% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -1.57% | -1.89% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Feb 12 | SEC filing · Form 8-K | -1.57% | -1.89% | |
| Form S-8 ALNYLAM PHARMACEUTICALS, | SEC filing · Form S-8 | +1.33% | +3.92% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jan 11 | SEC filing · Form 8-K | -3.52% | -1.83% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Dec 10 | SEC filing · Form 8-K | +0.82% | +2.30% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Dec 02 | SEC filing · Form 8-K | +0.37% | -1.55% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +0.60% | -0.10% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Oct 30 | SEC filing · Form 8-K | +0.60% | -0.10% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 8-K | -0.41% | -1.46% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Sep 12 | SEC filing · Form 8-K | -0.23% | -0.79% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Sep 08 | SEC filing · Form 8-K | -0.03% | -1.92% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +10.55% | +12.07% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 31 | SEC filing · Form 8-K | +10.55% | +12.07% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jun 12 | SEC filing · Form 8-K | -0.04% | -1.45% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: May 08 | SEC filing · Form 8-K | +0.71% | +0.10% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -3.29% | -0.78% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: May 01 | SEC filing · Form 8-K | -3.29% | -0.78% | |
| Form DEFA14A ALNYLAM PHARMACEUTICALS, | SEC filing · Form DEFA14A | -1.11% | +2.85% | |
| Form ARS ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | -0.95% | -3.13% | |
| Form DEF 14A ALNYLAM PHARMACEUTICALS, For: May 08 | SEC filing · Form DEF | -0.95% | -3.13% | |
| Form DEFA14A ALNYLAM PHARMACEUTICALS, | SEC filing · Form DEFA14A | -0.95% | -3.13% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Mar 20 | SEC filing · Form 8-K | +1.54% | +8.22% | |
| Form PRE 14A ALNYLAM PHARMACEUTICALS, For: May 08 | SEC filing · Form PRE | +0.06% | +4.29% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Mar 03 | SEC filing · Form 8-K | +1.32% | +1.46% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +2.62% | +3.21% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Feb 13 | SEC filing · Form 8-K | +2.62% | +3.21% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jan 12 | SEC filing · Form 8-K | +0.00% | +7.61% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -1.99% | -3.20% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Oct 31 | SEC filing · Form 8-K | -1.99% | -3.20% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -1.20% | +7.44% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 01 | SEC filing · Form 8-K | -1.20% | +7.44% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: May 16 | SEC filing · Form 8-K | +0.58% | +0.12% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -1.69% | -0.33% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: May 02 | SEC filing · Form 8-K | -1.69% | -0.33% | |
| Form ARS ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | -0.49% | -0.56% | |
| Form DEF 14A ALNYLAM PHARMACEUTICALS, For: May 16 | SEC filing · Form DEF | -0.49% | -0.56% | |
| Form DEFA14A ALNYLAM PHARMACEUTICALS, | SEC filing · Form DEFA14A | -0.49% | -0.56% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Mar 04 | SEC filing · Form 8-K | +0.84% | +0.50% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +0.03% | -0.68% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Feb 15 | SEC filing · Form 8-K | -1.12% | -1.71% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jan 12 | SEC filing · Form 8-K | -0.58% | +0.10% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jan 07 | SEC filing · Form 8-K | -1.14% | +3.98% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -1.97% | -0.50% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Nov 02 | SEC filing · Form 8-K | -1.97% | -0.50% |
Keep exploring
More ALNY: earnings → · analyst actions → · ALNY overview →
Other Healthcare names and their SEC filings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ENDOCYTE (ECYT) | 671 | -0.08% | 46% |
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its SEC filings — that is what the link opens.